Bildnachweis: NVision.
Fresh capital and a strategic pivot: how Ulm-based deeptech company NVision is transforming from a sensing hardware provider into a holistic ‘compute and validate’ platform for the pharmaceutical industry.
NVision initially made waves with Polaris, a quantum-enhanced MRI platform that reveals real-time metabolic treatment responses, replacing months of waiting with actionable biological data. Now, NVision is diving into quantum computing by integrating newly discovered molecule-based qubits directly onto chips to create ‘photonic integrated quantum circuits’ (PIQC). ‘It was not part of the original business plan, but it also was not an accident in the simplistic sense,’ clarifies Sella Brosh, M.D., co-founder and CEO of NVision. Having discovered molecules with long-lived spin coherence during the development of Polaris, he rejects the notion of a random pivot: ‘Both Polaris and PIQC emerge from the same molecular quantum engineering platform. One uses quantum control for sensing and biomarkers, the other for computation.’
The USD 55 million abbott boost
This unified vision recently convinced global diagnostics giant Abbott to anchor a USD 55 million series B financing round, bringing NVision’s total capital to USD 120 million. ‘We are not building an MRI company in the traditional sense,’ emphasises Brosh. While AI accelerates theoretical drug discovery, he views real-world clinical validation as the ultimate hurdle: ‘But as discovery accelerates, validation becomes the bottleneck. You need better biomarkers. The core value is the biomarker: the ability to observe metabolism and treatment response in living biology, in real time.’
Industrialising quantum technology
The fresh capital will fuel deployments across approximately 20 centres globally by year-end, including Memorial Sloan Kettering and the Technical University of Munich. To seamlessly integrate quantum technology into standard hospital workflows, the founder focuses heavily on scaling: ‘We are not trying to keep quantum technology inside specialised labs. We are trying to industrialise it.’ He embraces the logistical challenges of manufacturing and deployment: ‘These are challenging problems, but they are also the kind of problems you want to have because they reflect real-world adoption.’
The ‘quantum health’ era
‘I believe healthcare is entering a new era in which biology becomes increasingly computable and measurable in real time,’ Brosh predicts. In this emerging ‘quantum health’ space, computing optimises therapies upstream, while sensors like Polaris deliver real-time biological feedback downstream. For the pharmaceutical industry, this continuous ‘design, measure, learn, redesign’ loop promises to drastically compress the cycle of proving whether a new cancer drug actually works in humans.
